Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer

Yu Chieh Lee; Chii Hong Lee; Hsiang Ping Tsai; Herng Wei An; Chi-Ming Lee; Jen Chine Wu; Chien Shu Chen; Shih Hao Huang; Jaulang Hwang; Kur Ta Cheng; Phui Ly Leiw; Chi Long Chen; Chun Mao Lin

doi:10.1371/journal.pone.0132579

Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer

Yu Chieh Lee, Chii Hong Lee, Hsiang Ping Tsai, Herng Wei An, Chi-Ming Lee, Jen Chine Wu, Chien Shu Chen, Shih Hao Huang, Jaulang Hwang, Kur Ta Cheng, Phui Ly Leiw, Chi Long Chen, Chun Mao Lin

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)

Abstract

DNA topoisomerase I (TOP1) levels of several human neoplasms are higher than those of normal tissues. TOP1 inhibitors are widely used in treating conventional therapy-resistant ovarian cancers. However, patients may develop resistance to TOP1 inhibitors, hampering chemotherapy success. In this study, we examined the mechanisms associated with the development of camptothecin (CPT) resistance in ovarian cancers and identified evodiamine (EVO), a natural product with TOP1 inhibiting activity that overcomes the resistance. The correlations among TOP1 levels, cancer staging, and overall survival (OS) were analyzed. The effect of EVO on CPT-resistant ovarian cancer was evaluated in vitro and in vivo. TOP1 was associated with poor prognosis in ovarian cancers (p = 0.024). EVO induced apoptosis that was detected using flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The tumor size decreased significantly in the EVO treatment group compared with the control group (p <0.01) in a xenograft mouse model. Effects of drugs targeting TOP1 for prognosis and therapy in CPT-resistant ovarian cancer are anticipated. EVO with TOP1 can be developed as an antiproliferative agent for overcoming CPT resistance in ovarian cancers.

Original language	English
Article number	e0132579
Journal	PLoS ONE
Volume	10
Issue number	7
DOIs	https://doi.org/10.1371/journal.pone.0132579
Publication status	Published - Jul 24 2015

ASJC Scopus subject areas

General

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0132579

Cite this

@article{4123e794ca8a4ce49b094458d7740e9b,

title = "Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer",

abstract = "DNA topoisomerase I (TOP1) levels of several human neoplasms are higher than those of normal tissues. TOP1 inhibitors are widely used in treating conventional therapy-resistant ovarian cancers. However, patients may develop resistance to TOP1 inhibitors, hampering chemotherapy success. In this study, we examined the mechanisms associated with the development of camptothecin (CPT) resistance in ovarian cancers and identified evodiamine (EVO), a natural product with TOP1 inhibiting activity that overcomes the resistance. The correlations among TOP1 levels, cancer staging, and overall survival (OS) were analyzed. The effect of EVO on CPT-resistant ovarian cancer was evaluated in vitro and in vivo. TOP1 was associated with poor prognosis in ovarian cancers (p = 0.024). EVO induced apoptosis that was detected using flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The tumor size decreased significantly in the EVO treatment group compared with the control group (p <0.01) in a xenograft mouse model. Effects of drugs targeting TOP1 for prognosis and therapy in CPT-resistant ovarian cancer are anticipated. EVO with TOP1 can be developed as an antiproliferative agent for overcoming CPT resistance in ovarian cancers.",

author = "Lee, {Yu Chieh} and Lee, {Chii Hong} and Tsai, {Hsiang Ping} and An, {Herng Wei} and Chi-Ming Lee and Wu, {Jen Chine} and Chen, {Chien Shu} and Huang, {Shih Hao} and Jaulang Hwang and Cheng, {Kur Ta} and Leiw, {Phui Ly} and Chen, {Chi Long} and Lin, {Chun Mao}",

note = "Publisher Copyright: {\textcopyright} 2015 Lee et al.",

year = "2015",

month = jul,

day = "24",

doi = "10.1371/journal.pone.0132579",

language = "English",

volume = "10",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "7",

}

TY - JOUR

T1 - Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer

AU - Lee, Yu Chieh

AU - Lee, Chii Hong

AU - Tsai, Hsiang Ping

AU - An, Herng Wei

AU - Lee, Chi-Ming

AU - Wu, Jen Chine

AU - Chen, Chien Shu

AU - Huang, Shih Hao

AU - Hwang, Jaulang

AU - Cheng, Kur Ta

AU - Leiw, Phui Ly

AU - Chen, Chi Long

AU - Lin, Chun Mao

PY - 2015/7/24

Y1 - 2015/7/24

N2 - DNA topoisomerase I (TOP1) levels of several human neoplasms are higher than those of normal tissues. TOP1 inhibitors are widely used in treating conventional therapy-resistant ovarian cancers. However, patients may develop resistance to TOP1 inhibitors, hampering chemotherapy success. In this study, we examined the mechanisms associated with the development of camptothecin (CPT) resistance in ovarian cancers and identified evodiamine (EVO), a natural product with TOP1 inhibiting activity that overcomes the resistance. The correlations among TOP1 levels, cancer staging, and overall survival (OS) were analyzed. The effect of EVO on CPT-resistant ovarian cancer was evaluated in vitro and in vivo. TOP1 was associated with poor prognosis in ovarian cancers (p = 0.024). EVO induced apoptosis that was detected using flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The tumor size decreased significantly in the EVO treatment group compared with the control group (p <0.01) in a xenograft mouse model. Effects of drugs targeting TOP1 for prognosis and therapy in CPT-resistant ovarian cancer are anticipated. EVO with TOP1 can be developed as an antiproliferative agent for overcoming CPT resistance in ovarian cancers.

AB - DNA topoisomerase I (TOP1) levels of several human neoplasms are higher than those of normal tissues. TOP1 inhibitors are widely used in treating conventional therapy-resistant ovarian cancers. However, patients may develop resistance to TOP1 inhibitors, hampering chemotherapy success. In this study, we examined the mechanisms associated with the development of camptothecin (CPT) resistance in ovarian cancers and identified evodiamine (EVO), a natural product with TOP1 inhibiting activity that overcomes the resistance. The correlations among TOP1 levels, cancer staging, and overall survival (OS) were analyzed. The effect of EVO on CPT-resistant ovarian cancer was evaluated in vitro and in vivo. TOP1 was associated with poor prognosis in ovarian cancers (p = 0.024). EVO induced apoptosis that was detected using flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The tumor size decreased significantly in the EVO treatment group compared with the control group (p <0.01) in a xenograft mouse model. Effects of drugs targeting TOP1 for prognosis and therapy in CPT-resistant ovarian cancer are anticipated. EVO with TOP1 can be developed as an antiproliferative agent for overcoming CPT resistance in ovarian cancers.

UR - http://www.scopus.com/inward/record.url?scp=84942060624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942060624&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0132579

DO - 10.1371/journal.pone.0132579

M3 - Article

C2 - 26207989

AN - SCOPUS:84942060624

SN - 1932-6203

VL - 10

JO - PLoS ONE

JF - PLoS ONE

IS - 7

M1 - e0132579

ER -

Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this